Bladder cancer
Bladder cancer is the most common malignant tumor of the urinary system, and its incidence rate ranks first among malignant tumors of the urinary system. The cause of the disease is still unclear, but it is generally believed to be related to frequent contact with carcinogens such as naphthylamine and benzidine. Dyes, rubber, plastic products, paints, detergents, etc. commonly seen in daily life also have potential carcinogenic risks. Smoking is not only harmful to the respiratory system, but also causes bladder cancer. In addition, certain diseases such as leukoplakia, glandular cystitis, urethral stones, and urine retention may also induce bladder cancer. The incidence rate of bladder cancer in men and women is about 5:2, and there are about 54,500 new cases in the United States each year (estimated in 1997).
Related Drugs
Hydroxycamptothecin for injection
Indication: Anti-tumor drug, suitable for primary liver cancer, gastric cancer, bladder cancer, rectal cancer, non-small cell lung cancer, head and neck epithelial cancer, leukemia and other malignant tumors.
Manufacturer:
Fresenius Kabi (Wuhan) Pharmaceutical Co., Ltd.
Hydroxycamptothecin for injection
Indication: Applicable to primary liver cancer, gastric cancer, bladder cancer, colorectal cancer, head and neck epithelial cancer, leukemia, etc.
Manufacturer:
Fresenius Kabi (Wuhan) Pharmaceutical Co., Ltd.
Hydroxycamptothecin for injection
Indication: Anti-tumor drug, suitable for primary liver cancer, gastric cancer, bladder cancer, rectal cancer, non-small cell lung cancer, head and neck epithelial cancer, leukemia and other malignant tumors.
Hydroxycamptothecin for injection
Indication: Anti-tumor drug, suitable for primary liver cancer, gastric cancer, bladder cancer, rectal cancer, non-small cell lung cancer, head and neck epithelial cancer, leukemia and other malignant tumors.
Manufacturer:
ShenZhen Main Luck Pharmaceuticals Inc
Hydroxycamptothecin for injection
Indication: It is suitable for malignant tumors such as primary liver cancer, gastric cancer, bladder cancer, rectal cancer, non-small cell lung cancer, head and neck epithelial cancer, leukemia, etc.
Hydroxycamptothecin for injection
Indication: Anti-tumor drug, suitable for primary liver cancer, gastric cancer, bladder cancer, rectal cancer, non-small cell lung cancer, head and neck epithelial cancer, leukemia and other malignant tumors.
Manufacturer:
Sinopharm Group Luya(Shandong)Pharmaceutical Co., Ltd.
Hydroxycamptothecin for injection
Indication: Anti-tumor drug, suitable for primary liver cancer, gastric cancer, bladder cancer, rectal cancer, non-small cell lung cancer, head and neck epithelial cancer, leukemia and other malignant tumors.
Manufacturer:
Fresenius Kabi (Wuhan) Pharmaceutical Co., Ltd.
Recombinant human interleukin-2 (125Ala) for injection
Indication: 1. It is used for the treatment of malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, lung cancer, etc., and for the control of cancerous pleural effusion and ascites. It can also be used for the cultivation of lymphokine-activated killer cells.
Manufacturer:
Beijing SL Pharmaceutical Co., Ltd.
Recombinant human interleukin-2 (125Ala) for injection
Indication: 1. It is used for the treatment of malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, lung cancer, etc., and for the control of cancerous pleural effusion and ascites. It can also be used for the cultivation of lymphokine-activated killer cells.
Manufacturer:
Beijing SL Pharmaceutical Co., Ltd.
Recombinant human interleukin-2 (125Ala) for injection
Indication: 1. It is used for the treatment of malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, lung cancer, etc., and for the control of cancerous pleural effusion and ascites. It can also be used for the cultivation of lymphokine-activated killer cells.
Manufacturer:
Beijing SL Pharmaceutical Co., Ltd.